Yogish Kudva is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 14 Aug 2020.
Clinical trials
- PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
Sponsor: Mayo Clinic
- A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
Sponsor: Tandem Diabetes Care, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20255 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year202512 payments
- SANOFI-AVENTIS U.S. LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
72.2%Insulin Analog25.6%Lantus Solostar23%Tresiba Flextouch U-10022%Novolog19%Humalog17%Novolog Flexpen11%Lantus9%Part D<11 patientsGLP-1 receptor agonist21.5%Ozempic52%Mounjaro30%Trulicity18%Part D<11 patients+ 5 more classes in this area
Cardiovascular
18.5%Cholesterol absorption inhibitor10%Ezetimibe100%Part D≥18 patientsStatin8.5%Atorvastatin Calcium70%Rosuvastatin Calcium30%Part D<11 patientsCancer & immunology
5%Calcineurin inhibitor5%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial
Mayo Clinic Rochester
FY2026$318,445R01DK137868
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”